PMID- 21496344
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20211203
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 30
IP  - 1
DP  - 2011 Apr 17
TI  - Antisense oligodeoxynucleotides targeting ATM strengthen apoptosis of laryngeal 
      squamous cell carcinoma grown in nude mice.
PG  - 43
LID - 10.1186/1756-9966-30-43 [doi]
AB  - BACKGROUND: To conserve laryngeal function and elevate living quality of 
      laryngeal squamous cell carcinoma (LSCC) patients, we designed antisense 
      oligodeoxynucleotides (AS-ODNs) to reduce expression of ATM and to enhance the 
      apoptosis of hep-2 (Human epidermoid laryngeal carcinoma) cells to radiation in 
      vitro and in vivo. METHODS: The expression of ATM mRNA and protein in hep-2 cells 
      were examined by real-time quantitative PCR and western blotting respectively. 
      Clonogenic survival assay was carried out to detect the survival ability of hep-2 
      cells after irradiation, and analyzed the cell apoptosis by flow cytometry. The 
      volume of solid tumors was measured, while TUNEL assay and western blotting used 
      to analyze cell apoptosis and protein expression after irradiation. RESULTS: The 
      relative ATM mRNA and protein expression in hep-2 cells treated with ATM AS-ODNs 
      were decreased to 11.03 +/- 2.51% and 48.14 +/- 5.53% of that in untreated cells 
      respectively (P <0.05). After irradiation, the survival fraction (SF) of cells 
      treated with ATM AS-ODNs was lower than that of other groups at the same dose of 
      radiation (P < 0.05). The inhibition rate in hep-2 cells solid tumor exposed to 
      X-ray alone was 5.95 +/- 4.52%, while it was 34.28 +/- 2.43% in the group which 
      irradiated in combination with the treatment of ATM AS-ODNs (P < 0.05). The 
      apoptotic index for the group irradiated in combination with ATM AS-ODNs 
      injection was 17.12 +/- 4.2%, which was significantly higher than that of others (P 
      < 0.05). CONCLUSION: AS-ODNs of ATM reduce ATM expression and enhance hep-2 cells 
      apoptosis to radiation in vitro and in vivo.
FAU - Feng, Jun
AU  - Feng J
AD  - Department of Otolaryngology-Head and Neck Surgery, West China hospital of 
      Sichuan University, Chengdu, PR China.
FAU - Zou, Jian
AU  - Zou J
FAU - Li, Li
AU  - Li L
FAU - Zhao, Yongsheng
AU  - Zhao Y
FAU - Liu, Shixi
AU  - Liu S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110417
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.11.1 (ATM protein, human)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
RN  - EC 2.7.11.1 (Atm protein, mouse)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - *Apoptosis
MH  - Ataxia Telangiectasia Mutated Proteins
MH  - Carcinoma, Squamous Cell/genetics/pathology/*therapy
MH  - Cell Cycle Proteins/*antagonists & inhibitors/genetics
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/*antagonists & inhibitors/genetics
MH  - Flow Cytometry
MH  - Genetic Therapy
MH  - Laryngeal Neoplasms/genetics/pathology/*therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - *Oligonucleotides, Antisense
MH  - Protein Serine-Threonine Kinases/*antagonists & inhibitors/genetics
MH  - RNA, Messenger/metabolism
MH  - Transfection
MH  - Tumor Suppressor Proteins/*antagonists & inhibitors/genetics
PMC - PMC3097000
EDAT- 2011/04/19 06:00
MHDA- 2011/11/04 06:00
PMCR- 2011/04/17
CRDT- 2011/04/19 06:00
PHST- 2010/12/27 00:00 [received]
PHST- 2011/04/17 00:00 [accepted]
PHST- 2011/04/19 06:00 [entrez]
PHST- 2011/04/19 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
PHST- 2011/04/17 00:00 [pmc-release]
AID - 1756-9966-30-43 [pii]
AID - 10.1186/1756-9966-30-43 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2011 Apr 17;30(1):43. doi: 10.1186/1756-9966-30-43.